Full-Time

Senior Manager

Go To Market

Confirmed live in the last 24 hours

Ceribell

Ceribell

201-500 employees

EEG devices for monitoring brain activity

Healthcare

Compensation Overview

$170k - $200kAnnually

+ Annual Bonus + Equity

Senior

Sunnyvale, CA, USA

Hybrid position requiring in-office presence 2-3 days a week.

Category
General Marketing
Growth Marketing
Growth & Marketing
Required Skills
Sales
Data Analysis
Requirements
  • Bachelor’s degree in Marketing, Business, or a related field; MBA preferred.
  • 5+ years of experience in GTM strategy, product, product marketing, consulting, or related roles, preferably in the healthcare or medical technology industry.
  • Strong analytical skills with the ability to translate data into actionable insights.
  • Proven ability to work cross-functionally and drive alignment in a fast-paced environment.
  • Excellent verbal and written communication skills.
  • Direct sales experience preferred, not required.
Responsibilities
  • Conduct market analysis to identify customer needs, growth opportunities, competitive threats, and emerging trends. Develop comprehensive GTM strategies that support Ceribell’s goals.
  • Define and execute on key product positioning and messaging that resonates with target audiences across channels.
  • Inform feature or product launches through direct feedback from sales team and customers via targeted discussions in the field.
  • Work closely with Product, Sales, Marketing, and Customer Success teams to drive alignment on GTM initiatives and support strategic decision-making.
  • Develop and implement GTM tools, training materials, and resources to equip the sales team for successful engagements.
  • Establish KPIs and track the performance of GTM initiatives, adapting strategies based on results and data insights.
  • Serve as a key liaison between customers, the sales team, and internal teams, providing valuable insights into customer needs and feedback on products and GTM approaches.

Ceribell focuses on developing medical devices that utilize electroencephalogram (EEG) technology to monitor brain activity. Their main product, the Ceribell EEG Headband and Recorder, is designed for use by trained healthcare providers in professional settings. These devices help gather important data about a patient's brain activity, which healthcare professionals can analyze to make informed treatment decisions, especially in urgent situations like Nonconvulsive Status Epilepticus (NCSE), where timely intervention is crucial. Unlike some other EEG devices, Ceribell's products do not provide diagnostic conclusions or automated alerts; they serve solely as tools for data collection. Ceribell differentiates itself by focusing on the speed and efficiency of data gathering, which is vital in critical care scenarios. The company's goal is to enhance the ability of healthcare providers to monitor and respond to neurological conditions effectively.

Company Stage

Series C

Total Funding

$146.9M

Headquarters

Mountain View, California

Founded

2014

Growth & Insights
Headcount

6 month growth

11%

1 year growth

25%

2 year growth

63%
Simplify Jobs

Simplify's Take

What believers are saying

  • Ceribell's recent $102 million equity investment and $50 million financing round indicate strong financial backing for expansion and product development.
  • The appointment of experienced leaders like Sean Manni and Joshua Copp positions the company for strategic growth and operational excellence.
  • Recognition by Fast Company as one of the World's Most Innovative Companies highlights Ceribell's industry impact and potential for continued innovation.

What critics are saying

  • The reliance on healthcare providers to interpret EEG data may limit the device's adoption in settings with less specialized staff.
  • The competitive landscape in medical devices and AI-powered diagnostics could pose challenges to Ceribell's market share.

What makes Ceribell unique

  • Ceribell's AI-powered point-of-care EEG system is a first-of-its-kind technology, setting it apart from traditional EEG devices.
  • The company's focus on rapid, easy-to-use brain monitoring solutions for time-critical conditions like NCSE provides a unique value proposition.
  • FDA Breakthrough Device Designation for delirium detection further validates Ceribell's innovative approach in neurodiagnostics.

Help us improve and share your feedback! Did you find this helpful?